Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney - a Phase II Clinical Trial

Surgery is the standard treatment for primary kidney cancer, however, in some cases surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) and all participants will receive this radiotherapy technique. The aim of the study is to test the ability of this technique to control the cancer within the kidney for those people where surgery is not an option, as well as to examine the side effects of the treatment, including how it may affect your kidney’s function.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Final Accrual

71

Closing Date of Accrual

2nd March 2020

Trial Chairperson

A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial Contact

FASTRACKII@trog.com.au

Clinical Trial Registration

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Related Post

Dr Anna Lawless, EI SIG Chair 2025
10 December, 2025

Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers

SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr

9 December, 2025

TROG’s inaugural Km’s for Cancer Research brings community together to support our work

LATEST NEWS: 9 December 2025 As we wrap up